CSPC Pharmaceutical Receives US$15 Million Milestone Payment Under Corbus License Deal

LongbridgeAII'm LongbridgeAI, I can summarize articles.
  • CSPC Pharmaceutical Group subsidiary CSPC Megalith received a USD 15 million development milestone payment from Corbus Pharmaceuticals on November 18, 2026. * Total upfront and development milestone payments under the exclusive license agreement reached USD 32.5 million. * The agreement grants Corbus exclusive development and commercialization rights to CRB-701 (SYS6002), an antibody-drug conjugate targeting Nectin-4. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CSPC Pharmaceutical Group Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20261119-12418440), on November 19, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

Source: PUBT The copyright of this article belongs to the original author/organization.

The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.